MX2018015873A - Preparacion de derivados del factor xa. - Google Patents

Preparacion de derivados del factor xa.

Info

Publication number
MX2018015873A
MX2018015873A MX2018015873A MX2018015873A MX2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A
Authority
MX
Mexico
Prior art keywords
protein
derivatives
factor
preparation
chromatograph
Prior art date
Application number
MX2018015873A
Other languages
English (en)
Spanish (es)
Inventor
Karbarz Mark
B Conley Pamela
Genmin Lu
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018015873(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2018015873A publication Critical patent/MX2018015873A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018015873A 2016-06-17 2017-06-19 Preparacion de derivados del factor xa. MX2018015873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (1)

Publication Number Publication Date
MX2018015873A true MX2018015873A (es) 2019-08-12

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015873A MX2018015873A (es) 2016-06-17 2017-06-19 Preparacion de derivados del factor xa.

Country Status (21)

Country Link
US (4) US10604748B2 (cg-RX-API-DMAC7.html)
EP (3) EP3472314B1 (cg-RX-API-DMAC7.html)
JP (3) JP6959268B2 (cg-RX-API-DMAC7.html)
KR (1) KR102373215B1 (cg-RX-API-DMAC7.html)
CN (3) CN116425860B (cg-RX-API-DMAC7.html)
AU (2) AU2017283720C1 (cg-RX-API-DMAC7.html)
CL (2) CL2018003654A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019000120A2 (cg-RX-API-DMAC7.html)
DK (1) DK3472314T3 (cg-RX-API-DMAC7.html)
EA (1) EA037815B1 (cg-RX-API-DMAC7.html)
ES (2) ES3038834T3 (cg-RX-API-DMAC7.html)
HU (1) HUE054597T2 (cg-RX-API-DMAC7.html)
IL (1) IL263591B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018015873A (cg-RX-API-DMAC7.html)
PE (1) PE20190661A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018502614A1 (cg-RX-API-DMAC7.html)
PL (1) PL3472314T3 (cg-RX-API-DMAC7.html)
PT (1) PT3472314T (cg-RX-API-DMAC7.html)
SG (1) SG11201810915QA (cg-RX-API-DMAC7.html)
SI (1) SI3472314T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017219034A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
EP2948168B1 (en) * 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CN116425860B (zh) * 2016-06-17 2025-03-04 阿雷克森制药公司 因子xa衍生物的制备
JP2021527435A (ja) 2018-06-19 2021-10-14 アレクシオン ファーマシューティカルズ, インコーポレイテッド 第Xa因子阻害剤に対する解毒剤
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
US7598276B2 (en) 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
EP3824902A1 (en) * 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CN102316893B (zh) 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
SG11201408028YA (en) * 2012-06-14 2015-01-29 Portola Pharm Inc METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
EP2948168B1 (en) * 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
SG11201601221XA (en) * 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
KR20250150675A (ko) * 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형
CN116425860B (zh) * 2016-06-17 2025-03-04 阿雷克森制药公司 因子xa衍生物的制备

Also Published As

Publication number Publication date
EP3926044B1 (en) 2025-06-04
US10954504B2 (en) 2021-03-23
DK3472314T3 (da) 2021-07-26
PH12018502614A1 (en) 2019-09-30
EP4588932A2 (en) 2025-07-23
CN110167575B (zh) 2024-03-15
EP3472314A2 (en) 2019-04-24
EP3926044A1 (en) 2021-12-22
WO2017219034A3 (en) 2019-03-14
EP4588932A3 (en) 2025-10-01
SG11201810915QA (en) 2019-01-30
US20240076642A1 (en) 2024-03-07
WO2017219034A2 (en) 2017-12-21
IL263591A (en) 2019-02-03
PE20190661A1 (es) 2019-05-08
US11845966B2 (en) 2023-12-19
SI3472314T1 (sl) 2021-11-30
US20200208131A1 (en) 2020-07-02
US20210348149A1 (en) 2021-11-11
PT3472314T (pt) 2021-06-18
ES3038834T3 (en) 2025-10-15
IL263591B2 (en) 2023-03-01
KR20190019134A (ko) 2019-02-26
EA037815B1 (ru) 2021-05-25
JP7273918B2 (ja) 2023-05-15
CN116425860B (zh) 2025-03-04
EP3472314B1 (en) 2021-05-05
JP6959268B2 (ja) 2021-11-02
CL2020001733A1 (es) 2020-09-25
US20170369862A1 (en) 2017-12-28
AU2017283720B2 (en) 2022-11-17
AU2023200825A1 (en) 2023-03-16
US10604748B2 (en) 2020-03-31
ES2875538T3 (es) 2021-11-10
JP2019528242A (ja) 2019-10-10
JP2022000477A (ja) 2022-01-04
HUE054597T2 (hu) 2021-09-28
CN118271391A (zh) 2024-07-02
CL2018003654A1 (es) 2019-01-25
BR112018075964A2 (pt) 2019-04-02
CN116425860A (zh) 2023-07-14
JP2023086970A (ja) 2023-06-22
AU2017283720A1 (en) 2019-01-03
KR102373215B1 (ko) 2022-03-10
PL3472314T3 (pl) 2021-11-22
IL263591B (en) 2022-11-01
EA201990052A1 (ru) 2019-05-31
CO2019000120A2 (es) 2019-03-29
CN110167575A (zh) 2019-08-23
CA3027457A1 (en) 2017-12-21
AU2017283720C1 (en) 2024-07-25
EP3472314A4 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
PH12018502614A1 (en) Preparation of factor xa derivatives
IN2013MU02145A (cg-RX-API-DMAC7.html)
MX2018002831A (es) Polipeptidos.
MY193249A (en) Anti-human cd19 antibodies with high affinity
EP4375371A3 (en) Methods for the manufacture of proteolytically processed polypeptides
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
MX2021006732A (es) Nanoemulsiones para bebidas producidas mediante un proceso de alto cizallamiento.
MX360855B (es) Procedimiento para la preparación de una composición que comprende complejos metálicos en una matriz orgánica aceitosa.
NZ711192A (en) Process for making benzoxazepin compounds
MX2019015499A (es) Método para producir d-psicosa a partir de un complejo de borato y d-psicosa usando cromatografía y composición que contiene d-psicosa.
MX2018004300A (es) Uso de nuevas mezclas de isomero de (e/z) ciclopentadecenona, produccion y su uso como sustancia aromatizante.
MX2018004299A (es) Metodo para la purificacion de ciclohexadec-8-en-1-ona.
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
MY195169A (en) Cyclic Ether Derivatives of Pyrazolo[1,5-A]Pyrimidine-3-Carboxyamide
BR112017025872A2 (pt) proteínas de ligação multiespecíficas
IN2013MU01113A (cg-RX-API-DMAC7.html)
GB2514940A (en) Process and method for the treatment of materials, materials thus obtained and uses of these materials
EA202190557A1 (ru) СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА
MX2015014193A (es) Metodo para separar y purificar lactoferrina humana recombinada a partir de semillas de arroz.
JO3712B1 (ar) طريقة لتحضير 1-(4-ميثان سلفونيل-2-تراي فلورو ميثيل-بنزيل)-2ميثيل-1h-بيرولو[2، 3-b]بيريدين-3-يل-حمض أسيتيك
EA201691510A1 (ru) Новые способы разделения горохового белка
EP4239329A3 (en) Method and apparatus
PH12014501220A1 (en) Removal of components from a starting material
NZ742210A (en) Neospora vaccine composition